JFG
RXRX icon

Jefferies Financial Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Jefferies Financial Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,110
Closed -$101K – 1820
2024
Q1 		$101K Sell
10,110
-169,890
-94% -$1.89M ﹤0.01% 1437
2023
Q4 		$1.77M Buy
180,000
+170,000
+1,700% +$1.21M 0.01% 760
2023
Q3 		$76.5K Buy
+10,000
New +$99.8K ﹤0.01% 1481

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jefferies Financial Group's RXRX Position: Q2 2024 in Review

Jefferies Financial Group sold out of Recursion Pharmaceuticals (RXRX) in Q2 2024, closing a stake of 10,110 shares — an estimated $101K sold.

Jefferies Financial Group first reported a position in RXRX in Q3 2023 and held it in 3 quarters. The position peaked at $1.77M in Q4 2023. 270 funds tracked by Wall St. Rank hold RXRX as of Q2 2024.

  • Jefferies Financial Group reported no remaining Recursion Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Jefferies Financial Group sold 10,110 Recursion Pharmaceuticals shares in Q2 2024, an estimated $101K.
  • Jefferies Financial Group first reported a position in Recursion Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Jefferies Financial Group's Recursion Pharmaceuticals position peaked at $1.77M in Q4 2023.
  • 270 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2024.

Based on Jefferies Financial Group's 13F filing for Q2 2024, filed 13 Aug 2024.